68.04 -0.22 (-0.32%)
Pre-Market: 6:46AM EST
Previous Close | 70.43 |
Open | 68.79 |
Bid | 68.35 x 800 |
Ask | 68.15 x 800 |
Day's Range | 68.09 - 69.28 |
52 Week Range | 39.37 - 76.26 |
Volume | 966,096 |
Avg. Volume | 919,464 |
Market Cap | 33.744B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.09 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.11 (0.16%) |
Ex-Dividend Date | Apr 30, 2021 |
1y Target Est | 75.82 |
Alcon’s Sue-Jean Lin Wins 2021 Dallas CIO of the Year
ALC earnings call for the period ending December 31, 2020.
Shares of Alcon (NYSE:ALC) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 8.89% over the past year to $0.41, which were in line with the estimate of $0.41. Revenue of $1,925,000,000 higher by 2.34% year over year, which beat the estimate of $1,890,000,000. Guidance Earnings guidance hasn't been issued by the company for now. View more earnings on ALC Revenue guidance hasn't been issued by the company for now. Technicals 52-week high: $76.26 Company's 52-week low was at $39.37 Price action over last quarter: Up 10.91% Company Profile Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.